Symmetric Antimicrobial Peptides RI8 and RW8 Kill MDR Bacteria and Outperform Antibiotics in Pneumonia Model
Symmetric palindromic peptides RI8/RW8 showed broad-spectrum MDR activity (MIC 2-16 μg/mL), protease resistance, dual membrane/DNA targeting, and outperformed levofloxacin for S. aureus pneumonia in mice.
Quick Facts
What This Study Found
RI8: MIC 2-16 μg/mL broad-spectrum, therapeutic index 39.4, <1% hemolysis. RW8: protease-resistant, 71.4% biofilm inhibition. Both: dual membrane/DNA mechanism, 2-5 log wound reduction, outperformed levofloxacin in pneumonia (3-5 vs 2 logs).
Key Numbers
How They Did This
Rational peptide design with (RRYY)2P(YYRR)2 scaffold, MIC/hemolysis/serum stability assays, MD simulations, biofilm assays, murine MDR wound and S. aureus pneumonia models.
Why This Research Matters
These peptides solve two major AMP problems: protease degradation and narrow spectrum. Their rational design creates a versatile platform for different infection types.
The Bigger Picture
The symmetric palindromic scaffold is a general design principle: one peptide architecture, two complementary variants optimized for different clinical scenarios (systemic vs topical).
What This Study Doesn't Tell Us
Mouse models. Manufacturing costs of designed peptides. Long-term resistance development not tested beyond initial assays. Pharmacokinetics need full characterization.
Questions This Raises
- ?Could RI8 and RW8 be combined for enhanced efficacy?
- ?Would the palindromic scaffold work with other amino acid sequences?
- ?What is the manufacturing cost at clinical scale?
Trust & Context
- Key Stat:
- Outperformed levofloxacin RI8/RW8 achieved 3-5 log bacterial reduction vs 2 logs for levofloxacin in S. aureus pneumonia model
- Evidence Grade:
- Comprehensive rational design study with in vitro, computational, and dual in vivo model validation. Strong translational potential.
- Study Age:
- Published in 2025.
- Original Title:
- Antimicrobial peptides RI8 and RW8 target bacterial membranes and genomic DNA to overcome drug resistance.
- Published In:
- Bioorganic chemistry, 172, 109599 (2026)
- Authors:
- Gao, Ziwei, Zhang, Meng-Yue, Cheng, Yan-Liang, Shi, Yi-Fan, Shan, Xiao-Le, Zhang, Zi-Xuan, Han, Yu-Ling, Li, Shuang
- Database ID:
- RPEP-15195
Evidence Hierarchy
Frequently Asked Questions
How are these peptides different from other antimicrobial peptides?
They have a unique symmetric, palindromic structure with a proline hinge that allows them to attack bacteria through two mechanisms simultaneously: disrupting cell membranes AND binding DNA. This dual attack makes resistance much harder to develop.
Are they better than antibiotics?
In a mouse pneumonia model, they killed 10-100× more S. aureus bacteria than levofloxacin (a strong antibiotic). They also restored immune function, which antibiotics alone don't do.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15195APA
Gao, Ziwei; Zhang, Meng-Yue; Cheng, Yan-Liang; Shi, Yi-Fan; Shan, Xiao-Le; Zhang, Zi-Xuan; Han, Yu-Ling; Li, Shuang. (2026). Antimicrobial peptides RI8 and RW8 target bacterial membranes and genomic DNA to overcome drug resistance.. Bioorganic chemistry, 172, 109599. https://doi.org/10.1016/j.bioorg.2026.109599
MLA
Gao, Ziwei, et al. "Antimicrobial peptides RI8 and RW8 target bacterial membranes and genomic DNA to overcome drug resistance.." Bioorganic chemistry, 2026. https://doi.org/10.1016/j.bioorg.2026.109599
RethinkPeptides
RethinkPeptides Research Database. "Antimicrobial peptides RI8 and RW8 target bacterial membrane..." RPEP-15195. Retrieved from https://rethinkpeptides.com/research/gao-2026-antimicrobial-peptides-ri8-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.